Pfizer
PFE
Market cap $149B

26.30 USD

+0.40

1.54%

At close Feb 21, 4:00 PM EST

After hours

26.28

-0.02

0.08%

1 day

1.54%

5 days

2.22%

1 month

-1.28%

3 months

4.66%

6 months

-9.40%

Year to date

-1.16%

1 year

-4.95%

5 years

-26.37%

10 years

-23.52%

About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Employees: 88,000

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 7,139 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

29% more first-time investments, than exits

New positions opened: 299 | Existing positions closed: 231

0.17% more ownership

Funds ownership: 65.43% [Q3] → 65.6% (+0.17%) [Q4]

3% less funds holding

Funds holding: 2,864 [Q3] → 2,786 (-78) [Q4]

5% less funds holding in top 10

Funds holding in top 10: 39 [Q3] → 37 (-2) [Q4]

7% less capital invested

Capital invested by funds: $108B [Q3] → $99.8B (-$8.08B) [Q4]

15% less call options, than puts

Call options by funds: $3.26B | Put options by funds: $3.86B

37% less repeat investments, than reductions

Existing positions increased: 883 | Existing positions reduced: 1,398

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$29

10%

upside

Avg. target

$30

16%

upside

High target

$33

25%

upside

5 analyst ratings

2 positive

40%

3 neutral

60%

0 negative

0%

Guggenheim Vamil Divan 50% 1-year accuracy 12 / 24 met price target	25%upside $33	Buy Reiterated	10 Feb 2025
Citigroup Andrew Baum 50% 1-year accuracy 3 / 6 met price target	10%upside $29	Neutral Maintained	28 Jan 2025
UBS Colin Bristow 12% 1-year accuracy 2 / 17 met price target	10%upside $29	Neutral Maintained	8 Jan 2025
Truist Securities Srikripa Devarakonda 34% 1-year accuracy 12 / 35 met price target	22%upside $32	Buy Maintained	18 Dec 2024
B of A Securities Tim Anderson 56% 1-year accuracy 5 / 9 met price target	10%upside $29	Neutral Reinstated	10 Dec 2024

See Analyst Rankings

Financial journalist opinion

Based on 93 articles about PFE published over the past 30 days

The Motley Fool

3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade

There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're looking for a way to raise the stream of passive income your portfolio produces or you simply want to outperform benchmark averages, adding some dividend-paying stocks to your portfolio is a smart way forward.

3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade

The Motley Fool

2 No-Brainer Healthcare Stocks to Buy With $500 Right Now

Looking for a good area in which to invest? Consider the healthcare sector.

2 No-Brainer Healthcare Stocks to Buy With $500 Right Now

Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports

Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends

The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annualized dividend income. I added to positions in Pfizer, Starwood Property Trust, and Reaves Utility Income Trust, focusing on undervalued stocks with strong dividend yields.

Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends

The Motley Fool

The Smartest Dividend Stocks to Buy With $1,000 Right Now

You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Might I suggest some dividend payers?

The Smartest Dividend Stocks to Buy With $1,000 Right Now

10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers

Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN ReFa/Ro: CAG, VZ, DOW, PFE, MRK GOGL, PK, PBR FRO, and TRMD averaged 40.36% net gains from reader data collected 2/17/25. Ten analysts target-augured January TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: CAG, VZ, PBR, DOW, PFE, GOGL, TRMD, PK, MRK, & FRO, boasting a 27.91% average target price upside estimate.

10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79.9% year-on-year. A key contributor to its strong performance was its Vyndaqel family, whose sales grew more than 60% year over year.

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Pfizer Stock's Upside Got Bigger

Pfizer Stock's Upside Got Bigger

Pfizer Stock's Upside Got Bigger

CNBC Television

Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.

Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.

See News Rankings

Charts implemented using Lightweight Charts™